
Hydroxychloroquine & COVID 19: Is It a Clinical "Bear Market" for the Drug?
Jason Pogue, PharmD, BCPS, BCIDP, answers questions about the emerging picture for hydroxychloroquine.
Segment Description: Jason Pogue, PharmD, BCPS, BCIDP, clinical pharmacist and professor in infectious diseases at the University of Michigan College of Pharmacy, speaks with Contagion about the emerging picture for hydroxychloroquine, a now-controversial drug which made headlines after showing promise in the lab against SARS-CoV-2.
The debate has been
A different publication, on use of the drug for out-patient prophylaxis, has offered less contested insight.























































































































































































































